Cellular Therapy for In Utero Repair of Myelomeningocele – The CuRe Trial Post author: Post published:April 20, 2026 Post category: Continue ReadingCellular Therapy for In Utero Repair of Myelomeningocele – The CuRe Trial
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Post author: Post published:April 20, 2026 Post category: Continue ReadingSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL Post author: Post published:April 20, 2026 Post category: Continue ReadingBAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia Post author: Post published:April 20, 2026 Post category: Continue ReadingAllogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study Post author: Post published:April 20, 2026 Post category: Continue ReadingGeriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS Post author: Post published:April 20, 2026 Post category: Continue ReadingCMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release Post author: Post published:April 20, 2026 Post category: Continue ReadingExpanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingIntracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) Post author: Post published:April 20, 2026 Post category: Continue ReadingA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
